Longeveron (LGVN) AI Stock Analysis

• Market Cap: $16.26M
• Dividend Yield: N/A
• Average Volume (3M): 473.11K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.54
• Revenue Growth: -22.41%
• EPS Growth: 78.88%
• Country: US
• Employees: 25
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.39
• Shares Outstanding: 19,848,877
• 10 Day Avg. Volume: 706,553
• 30 Day Avg. Volume: 473,105
• PEG Ratio: 0.02
• Price to Book (P/B): 1.18
• Price to Sales (P/S): 10.77
• P/FCF Ratio: -1.73
• Enterprise Value/Market Cap: 0.64
• Enterprise Value/Revenue: 7.18
• Enterprise Value/Gross Profit: 9.59
• Enterprise Value/Ebitda: -0.50
• 1Y Price Target: $3.50
• Price Target Upside: 455.56% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 40 Underperform
• Price Target: $0.58 ▼(-7.46% Downside)

Longeveron's overall stock score is heavily impacted by its poor financial performance and valuation metrics. The technical analysis also indicates bearish momentum. While there are some positive developments in clinical trials and corporate governance, these are overshadowed by financial instability and the risk of Nasdaq delisting.

Positive Factors

Patent Grant in Canada

The new patent in Canada extends Longeveron's intellectual property protection through 2037, enhancing its competitive position in the regenerative medicine market.

Strong Clinical Pipeline

A strong clinical pipeline with multiple FDA designations positions Longeveron for potential breakthroughs and long-term growth in the biotech sector.

Positive Clinical Trial Results

Positive trial results indicate potential for future product approvals, strengthening Longeveron's market position and revenue prospects.

Negative Factors

Declining Revenue

Significant revenue decline reflects reduced demand and operational challenges, potentially impacting long-term financial sustainability.

Financial Risks and Cash Runway

Limited cash runway highlights the urgent need for additional financing, posing a risk to ongoing operations and strategic initiatives.

Delay in BLA Filing

Delays in regulatory filings can postpone revenue generation and impact investor confidence, affecting long-term strategic goals.

Longeveron Business Overview & Revenue Model

Company Description

Longeveron Inc. (LGVN) is a biotechnology company focused on developing innovative cellular therapies to treat age-related and life-threatening conditions. The company primarily operates in the regenerative medicine sector, leveraging its proprietary technology to develop and manufacture products derived from mesenchymal stem cells. Longeveron’s core products include Lomecel-B, a cell therapy aimed at treating frailty in elderly patients, and other potential treatments for various cardiovascular and neurodegenerative diseases.

How the Company Makes Money

Longeveron generates revenue primarily through the development and commercialization of its cellular therapies. The company conducts clinical trials to advance its product candidates, which can lead to partnerships with larger pharmaceutical companies for further development and distribution. Additionally, Longeveron may receive funding through government grants or collaborations for research and development efforts. Key revenue streams include potential product sales from successful clinical trials, licensing agreements, and partnerships that may provide milestone payments and royalties based on future sales of its therapies.

Longeveron Financial Statement Overview

Summary

Longeveron faces significant financial challenges, with declining revenues, negative profitability, and cash flow issues. Despite low leverage, the inability to generate positive returns on equity and consistent negative cash flows highlight operational inefficiencies and financial instability.

Income Statement

Longeveron's income statement shows significant challenges, with declining revenue and negative profit margins. The TTM data reveals a revenue decrease of 30.68%, and the company has consistently reported negative net profit margins, with the TTM at -14.85%. Despite a relatively high gross profit margin of 74.88% in the TTM, the negative EBIT and EBITDA margins indicate operational inefficiencies and high costs relative to revenue.

Balance Sheet

The balance sheet reflects a low debt-to-equity ratio of 0.065 in the TTM, suggesting conservative leverage. However, the return on equity is negative, indicating that the company is not generating profits from its equity base. The equity ratio is not provided, but the overall financial health appears weak due to the negative ROE and declining equity over time.

Cash Flow

Cash flow analysis shows some improvement, with a positive free cash flow growth rate of 16.72% in the TTM. However, the operating cash flow remains negative, and the operating cash flow to net income ratio is unfavorable at -3.39, indicating cash flow challenges. The free cash flow to net income ratio is slightly positive, suggesting some alignment between cash flow and reported earnings.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.44M	2.39M	709.00K	1.22M	1.31M	5.63M
Gross Profit	1.08M	1.88M	221.00K	497.00K	590.00K	1.83M
EBITDA	-20.52M	-15.56M	-20.08M	-17.15M	-16.13M	-2.93M
Net Income	-21.34M	-15.97M	-21.41M	-18.84M	-17.05M	-3.72M
Balance Sheet
Total Assets	15.56M	25.56M	12.08M	27.41M	42.77M	9.24M
Cash, Cash Equivalents and Short-Term Investments	9.24M	19.23M	5.36M	19.66M	35.04M	816.00K
Total Debt	983.00K	1.45M	2.04M	2.60M	3.14M	4.14M
Total Liabilities	5.59M	3.67M	5.34M	6.91M	5.31M	7.28M
Stockholders Equity	9.97M	21.89M	6.74M	20.50M	37.45M	1.96M
Cash Flow
Free Cash Flow	-16.98M	-14.86M	-19.30M	-14.82M	-10.95M	-2.63M
Operating Cash Flow	-16.72M	-13.87M	-19.00M	-13.97M	-9.64M	-2.36M
Investing Cash Flow	-654.00K	-640.00K	8.19M	-677.00K	-10.70M	-261.50K
Financing Cash Flow	3.84M	28.79M	5.26M	-509.00K	45.17M	1.58M

Longeveron Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.63
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LGVN, the sentiment is Negative. The current price of 0.63 is below the 20-day moving average (MA) of 0.63, below the 50-day MA of 0.74, and below the 200-day MA of 1.16, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 42.43 is Neutral, neither overbought nor oversold. The STOCH value of 52.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LGVN.

Longeveron Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IBIO	55 Neutral	$63.19M	―	-54.50%	―	185.71%	79.03%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LGVN	40 Underperform	$16.26M	-0.58	-119.92%	―	-22.41%	78.88%
FBLG	38 Underperform	$16.83M	-0.68	-1292.87%	―	―	18.47%
EDSA	35 Underperform	$11.96M	-1.28	-69.64%	―	―	22.63%
CMMB	33 Underperform	$15.26M	-1.33	-73.63%	―	―	53.19%
PCSA	29 Underperform	$17.42M	-0.15	-270.74%	―	―	72.88%

Longeveron Corporate Events

Longeveron Announces Resignation of Board Members

On November 7, 2025, Longeveron Inc. announced the immediate resignation of Mr. Khoso Baluch and Ms. Neha Motwani from its Board of Directors. Their departures were not due to any disagreements with the company’s operations, policies, or management, suggesting a smooth transition without internal conflict.

Longeveron Appoints Dr. George Paletta to Board

On October 1, 2025, Longeveron Inc. announced the appointment of Dr. George Paletta to its Board of Directors. Dr. Paletta, an internationally recognized orthopedic surgeon and entrepreneur, brings extensive experience in medicine and business to the company. His appointment comes at a pivotal time for Longeveron as it advances its stem cell therapy pipeline, including a pivotal clinical trial in hypoplastic left heart syndrome with data expected in 2026. This strategic addition is expected to enhance Longeveron’s efforts in commercializing stem cell therapies, benefiting healthcare, patients, and shareholders.

Longeveron Faces Nasdaq Delisting Notice for Stock Price

On September 22, 2025, Longeveron Inc. received a notice from Nasdaq indicating that its Class A common stock failed to meet the $1.00 minimum bid price requirement for continued listing. The company has until March 23, 2026, to regain compliance by ensuring the bid price closes at $1.00 or more for at least ten consecutive business days. If compliance is not achieved, Longeveron may face delisting or seek an additional compliance period while assessing options to rectify the deficiency.